A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients

Ulcerative Colitis Clinical Trial

Official title:

A Multicenter International Study of the Long-term Safety of Infliximab (REMICADE) in Ulcerative Colitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00207688
• Other study ID #: CR004801
• Secondary ID: C0168T62
• Status: Completed
• Start date: August 31, 2004
• Est. completion date: September 9, 2015

Study information

• Verified date: July 2018
• Source: Janssen Research & Development, LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to evaluate long-term safety information of infliximab in patients who have participated in infliximab clinical studies in ulcerative colitis.

Description:

This is a long term, multicenter, international safety study to evaluate targeted long-term safety information on patients who have participated in infliximab(Remicade) clinical studies in ulcerative colitis that require long-term safety follow-up. All patients who received at least one dose of study drug (infliximab or placebo) in the primary studies (C0168T37 ,C0168T46, C0168T72) are eligible to participate in this long-term safety follow-up study (C0168T62). Patients will begin participation in C0168T62 at the time of their last safety visit in the primary study and will be followed for 5 years. No study agent will be administered. Information on deaths, serious infections, new malignancies (including colorectal cancer) and new autoimmune diseases and surgical procedures (including colectomy) and hospitalizations for the treatment of ulcerative colitis will be collected. Information about possible delayed allergic reactions (possible fever, rash, fatigue, joint pain) will also be collected if patients received infliximab after the end of the primary study. In addition, data on dysplasia of the colon will be collected from patients who were identified in the primary study to be at high-risk for colon cancer and were required per protocol to undergo a follow-up colonoscopy as part of long-term safety follow-up. All adverse events, including non-serious adverse events, will also be collected.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 505
• Est. completion date: September 9, 2015
• Est. primary completion date: September 9, 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• All patients enrolled in three Phase 3 Janssen-sponsored (C0168T37, C0168T46, C0168T72) infliximab clinical studies in ulcerative colitis that require long-term safety follow-up

• Patients must have received at least 1 dose of study agent to be eligible for participation in the study

Exclusion Criteria:

• Patients who refuse consent or are unwilling to respond to requests for long-term safety information within the required timeframe will be excluded. In addition, patients participating in a study extension to the primary study are not eligible for participation in the C0168T62 study during the study extension participation

Related Conditions & MeSH terms

• Colitis
• Colitis, Ulcerative
• Ulcer
• Ulcerative Colitis

Intervention

Drug:
• Infliximab 5 mg/kg
Patients who received infliximab 5 mg/kg from C0168T37, C0168T46, C0168T72 studies will be observed.
• Infliximab 10 mg/kg
Patients who received infliximab10 mg/kg from C0168T37, C0168T46, C0168T72 studies will be observed.
• Placebo
Patients who received placebo from C0168T37, C0168T46, C0168T72 studies will be observed.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Janssen Research & Development, LLC	Janssen Biologics BV

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Austria,  Belgium,  Canada,  Czechia,  Denmark,  France,  Germany,  Israel,  Netherlands,  New Zealand,  Switzerland,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients with adverse events as a measure of safety	Long-term safety will be evaluated by assessment of serious infections,new malignancies (including colorectal cancer), new autoimmune diseases, death, delayed hypersensitivity (serum sickness-like) reactions, or dysplasia of the colon and other non-serious adverse events. Non-serious adverse events will be collected for participants continuing at the beginning of collection of non-serious adverse events.	5 years
Secondary	Number of patients with malignancies by malignancy type	Number of patients with malignancies by malignancy type (ie, lymphoma, nonmelanoma skin cancers, other malignancies)	5 years
Secondary	Number of patients with serious infections by type of infection		5 years
Secondary	Number of patients with surgical procedures (including colectomy) for the treatment of ulcerative colitis		5 years
Secondary	Number of patients with hospitalizations for the treatment of ulcerative colitis		5 years

External Links

•   Multicenter International Study of the Long-term Safety of Infliximab (REMICADE®) in Ulcerative Colitis